Shares of Inovio Pharmaceuticals Inc (NYSEMKT:INO), saw unusually large options trading on Tuesday. Stock investors acquired 10,971 call options on the stock,American Banking and Market News reports. This is an increase of approximately 1,476% compared to the average daily volume of 696 call options. Inovio Pharmaceuticals Inc (NYSEMKT:INO), weekly performance is -3.24%. On last trading day company shares ended up $2.09. Analysts mean target price for the company is $4.80. Inovio Pharmaceuticals Inc (NYSEMKT:INO), distance from 50-day simple moving average (SMA50) is -26.66%.
Dendreon Corporation (NASDAQ:DNDN), gained 7.94% after the company announced data from ProACT and IMPACT studies on PROVENGE, or sipuleucel-T. Dendreon Corporation (NASDAQ:DNDN), fell 5.63% in last trading session and ended the day on $2.18. DNDN, Gross Margin is 41.40% and its return on assets is -54.60%. Dendreon Corporation (NASDAQ:DNDN), quarterly performance is -27.57%.
On May 13, 2014, Idera Pharmaceuticals Inc (NASDAQ:IDRA), reported Q1 EPS of ($0.12), $0.04 worse than the analyst estimate of ($0.08). Idera Pharmaceuticals Inc (NASDAQ:IDRA), shares moved down 5.43% in last trading session and was closed at $2.44, while trading in range of $2.43 – 2.61. Idera Pharmaceuticals Inc (NASDAQ:IDRA), year to date (YTD) performance is -47.30%.
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC)’s shares gained 1.51% to $1.31. The company on May 8 announced financial results for the quarter ended March 31, 2014. For the quarter ended March 31, 2014, the Company incurred a net loss of $3.2 million, or $0.05 per basic and diluted share, compared to a net loss of $5.0 million, or $0.10 per basic and diluted share for the quarter ended March 31, 2013. The Company reported that cash used in operations during the first quarter of 2014 was $2.6 million compared to $2.2 million during the first quarter of 2013. ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC), ended the last trading day at $1.26. Company weekly volatility is calculated as 7.05% and price to cash ratio as 2.92. ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC), showed a positive weekly performance of 5.00%.
On May 20, 2014, Synthetic Biologics Inc (NYSEMKT:SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced that Jeffrey Riley, CEO, is scheduled to present at the 3rd Annual Marcum LLP MicroCap Conference on Thursday, May 29, 2014 inNew York City at the Grand Hyatt Hotel. Mr. Riley is scheduled to present at 4:30 p.m. (Eastern Time). Synthetic Biologics Inc (NYSEMKT:SYN), weekly performance is 12.07%. On last trading day company shares ended up $1.30. Analysts mean target price for the company is $3.95. Synthetic Biologics Inc (NYSEMKT:SYN), distance from 50-day simple moving average (SMA50) is -44.20%.